What's Going On With Tonix Pharmaceuticals (TNXP) Stock?
Portfolio Pulse from Henry Khederian
Tonix Pharmaceuticals (NASDAQ:TNXP) shares surged 20% after announcing promising data on their mpox vaccine, TNX-801, at an immunology symposium. The vaccine offers single-dose protection, improved tolerability, and could outperform existing vaccines. Tonix is collaborating with Bilthoven Biologics for manufacturing processes.
September 09, 2024 | 3:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals' stock rose 20% following the announcement of promising data on their mpox vaccine, TNX-801. The vaccine offers advantages over existing options, potentially boosting investor confidence.
The announcement of promising data on TNX-801, a potential mpox vaccine, has led to a 20% increase in TNXP's stock price. The vaccine's advantages over existing options, such as single-dose protection and improved tolerability, are likely to boost investor confidence and interest in the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100